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Abstract: Adenovirus type 7 (Ad7) infection is associated with acute respiratory disease (ARD),
especially in military recruits living in close quarters. Recently, several outbreaks of Ad7 infections have
occurred in civilian populations, with some cases leading to death. However, the current Ad7 vaccine
is licensed for use only in military recruits because it utilizes an orally delivered wild type virus
which is shed in the stool for 28 days after immunization. This poses a safety risk due to the
possibility of virus spread to vulnerable populations. To address the need for a safer Ad7 vaccine
for use in civilian populations, we developed a single-cycle Ad7 virus (scAd7). This scAd7 virus
is deleted for the Ad7 fiber protein, so that viruses produced outside of complementing cells lines
lack this essential structural protein and have severely reduced infectivity. In vitro studies in
noncomplementing A549 cells showed that the scAd7 virus has genomic DNA replication kinetics
and Ad7 hexon expression similar to a replication-competent virus; however, virus progeny produced
after infection has impaired infectivity. Therefore, this scAd7 virus combines the safety advantages of
a replication-defective virus with the increased Ad7 gene expression of a replication-competent virus.
Due to these advantages, we believe that scAd7 viruses should be further studied as an alternative,
safer Adenovirus 7 vaccine.
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1. Introduction
Adenovirus type 7 (Ad7) infection is associated with acute respiratory disease (ARD),
fever, bronchitis, and pneumonia [1]. Young children, adults in crowded environments,
and immunocompromised patients are more susceptible to increased disease severity [2].
Ad7, along with Adenovirus type 4 (Ad4), causes significant morbidity in military recruits. Since 1971,
millions of military recruits have been vaccinated against Ad7 and Ad4 using an orally delivered,
lyophilized wild-type virus, which has been found to be effective at reducing the rates of respiratory
febrile illness [3–5]. However, this vaccine is only licensed for military populations because the wild
type virus can be shed in stool for up to 28 days post-vaccination [5,6]. Vaccinees are advised to exercise
caution during this time and limit contact with vulnerable populations, such as pregnant women,
immunocompromised people, or young children [6].
The Ad7 vaccine is only available to military recruits; however, the general population is also at
risk for severe infection. Recently, in 2018, 11 pediatric deaths were reported in a New Jersey hospital
as a result of Ad7 infection [7]. That same year, 35 confirmed cases of Adenovirus infection, leading to
1 death, were reported at the University of Maryland, with Ad7 as the causative type in at least 10 of
the reported cases [8]. Epidemic Ad7 infections cause significant morbidity worldwide in both military
and civilian populations [9–13].
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To address the need for a safe Ad7 vaccine for use in the general public, we developed a
single-cycle Ad7 virus that combines the safety advantages of a replication-defective virus with
the increased Ad7 gene expression of a replication-competent virus [14]. As a single-cycle virus,
the Ad7 genome is replicated ~10,000 fold after viral entry, leading to greater expression of Ad7
viral proteins. However, the virus produced outside of the complementing cell line lacks the fiber
protein. Fiber protein binding to cellular receptors is the primary mode of transduction for Adenovirus;
therefore, this fiberless Ad particle has severely reduced infectivity [15,16]. This greatly increases the
safety profile of this Ad7 vaccine while maintaining strong Ad7 protein expression, making it an ideal
candidate to explore for prevention of respiratory disease caused by Ad7 infection.
2. Materials and Methods
2.1. Ethics Statement
Human desmoglein (hDSG) transgenic mice were generously gifted from Dr. André Lieber [17].
Breeding colonies were established under the University of Nebraska—Lincoln (UNL) IACUC protocol
number 1243. Mice were housed in the Life Sciences Annex building on the UNL campus under
the Association for Assessment and Accreditation of Laboratory Animal Care (AALAC) guidelines
with animal use protocols approved by the UNL Animal Use and Care Committee under protocol
number 1241 approved 11/19/2015. All animal experiments were carried out in accordance with the
provisions of the Animal Welfare Act, PHS Animal Welfare Policy, the principles of the NIH Guide for
the Care and Use of Laboratory Animals, and the policies and procedures of UNL. All immunizations
and bleeds were performed under ketamine- and xylazine-induced anesthesia.
2.2. Ad7 Virus and DNA Purification
Adenovirus type 7 Gomen strain (ATCC VR-7) was purchased from ATCC. The Ad7 Gomen strain
was obtained from a throat swab of a California military recruit with pharyngitis in 1954 [18]. The strain
used to vaccinate military recruits is Ad7a; however, the Ad7 prototype Gomen strain was used
in this study due to commercial availability. Final amplification of the virus was performed in a
Corning 10-cell stack (~6300 cm2). Virus was amplified in 293 cells and purified on two sequential
CsCl ultracentrifuge gradients. Viral genomic DNA (gDNA) was purified using high-titer Ad7 virus
and the PureLink Viral RNA/DNA mini kit (Invitrogen, Carlsbad, CA, USA).
2.3. Development of an Ad7 Fiber Expressing Cell Line
The Ad7 fiber sequence was codon-optimized (co) and synthesized by Genscript.
Codon-optimization will improve protein expression levels and significantly reduce the possibility
of homologous recombination in vitro. The Ad7-Fiber-co was cloned into pCT-IRES-hrGFP and
transfected into 293 cells using Polyfect (Qiagen, Valencia, CA, USA). Twenty-four hours after
transfection, Geneticin was added (0.5 mg/mL). The cell line was passaged with Geneticin for several
weeks before Western blot analysis of Ad7 fiber expression and cryopreservation [19] (Figure S1).
2.4. Recombinant Ad7 Plasmid Construction
The complete Ad7 genome was cloned into a single low copy plasmid, and the E1 and E3 deleted
viruses expressing eGFPLuc were created as previously described [20] (Figure 1). Table 1A shows the
primers used to create the shuttle plasmid that was used to replace the fiber gene. The entire fiber
protein, from position 31320–32297 of the Ad7 genome, was deleted and replaced by a DsRed reporter
gene. The shuttle was created using an overlapping PCR product that contained a unique AscI
restriction enzyme site. A schematic representation of the cloning PCR fragment is shown (Figure S2A).
DsRed was fused to LoxP-Blasticidin-LoxP by overlapping PCR. Table 1B shows the primers used to
create the final PCR products (Figure S2B). AscI restriction sites were incorporated into the PCR primers
for ligation into the shuttle plasmids. Both PCR amplified transgenes were cloned into TOPO pCR8
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(Invitrogen, Carlsbad, CA, USA) and confirmed by sequencing. A final schematic representation of the
fragment used for homologous recombination is shown (Figure S2C).
To make the recombinant single cycle Adenovirus 7 (scAd7) plasmid, the shuttle plasmid was
digested with PmeI. The digested shuttle plasmid was co-transformed with 1.0µg of plasmid containing
the complete Ad7 genome (pAd7) into BJ5183 electrocompetent cells. Recombinants were selected
on LB containing Kanamycin and Blasticidin and then confirmed by restriction digestion analysis.
Positive recombinant clones were transformed into XL-1 cells and maxiprepped using the Qiagen HI
Speed Maxi kits (Qiagen, Valencia, CA, USA).
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Table 1. Primers for the creation and testing of the scAd7 vaccine. These primers were used for the
PCR amplification of the homologous flanking DNA used for inserting the DsRed gene in place of
the fiber gene (A). Ad7-Fib-Ins-F and Ad7-Fib-Ins OL-R primer pairs were used to amplify the 500 bp
region 5′ of the fiber gene. Ad7-Fib-Ins-OL-F and Ad7-Fib-Ins-R primer pairs were used to amplify
the 500 bp region 3′′ of the fiber gene. The two PCR products were combined, and the Ad7-Fib-Ins-F
and Ad7-Fib-Ins-R primers were used to amplify the overlapping PCR products. These primers
were used to create the DsRed floxed blasticidin gene for incorporation into the shuttle plasmid (B).
The overlapping PCR products were amplified similar to the previously described the shuttle PCR
product. The following PCR primer sets were used to quantitate the viral genes, cellular Actin gene,
and the introduced DsRed and GFP-Luc genes (C).
A. Primers for Ad7 Fiber Deletion/Gene Replacement Shuttle Plasmids.
Ad7-Fib-Ins-F GTTTAAACGAACGCGTGACCAAAGAGCTCAGAG
Ad7-Fib-Ins-OL-R AATAAACAAGTTAAACTTTATTTTGTGGCGCGCCCTGGGAAGAAAGACATGAAGATTGTG
Ad7-Fib-Ins-OL-F CACAATCTTCATGTCTTTCTTCCCAGGGCGCGCCACAAAATAAAGTTTAACTTGTTTATT
Ad7-Fib-Ins-R GTTTAAACTAATCTAAGTGAAATCAGAATGCGT
B. Primers for DsRed.
AscI-DsRed-F GGCGCGCCATGGCCTCCTCCGAGAACGTCATCA
DsRed-LBL-R AAGGGCGAATTCGGAGCCTGCTTTTTTCTACAGGAACAGGTGGTGGCGGCCCTCGGTG
DsRed-LBL-F CACCGAGGGCCGCCACCACCTGTTCCTGTAGAAAAAAGCAGGCTCCGAATTCGCCCTT
AscI-LBL-R GGCGCGCCCAAGAAAGCTGGGTCGAATTCGCCC
C. qPCR Primers
DsRed-F CACTACCTGGTGGAGTTCAAG DsRed-R GATGGTGTAGTCCTCGTTGTG
Ad7 Fiber-F GATTCCTTCAACCCTGTCTACC Ad7 Fiber-R CCGTCTGGGCTTTGTGTAA
Ad7 Hexon-F GGAACCTTACCCAGCCAATTA Ad7 Hexon-R AGTTGCTGGAGAAGGGAATG
ACTB gDNA-F GGCCTTGGAGTGTGTATTAAGT ACTB gDNA-R GGACATGCAGAAAGTGCAAAG
eGFPLuc-F CGGAAAGACGATGACGGAAA eGFPLuc-R CGGTACTTCGTCCACAAACA
2.5. Recombinant Ad7 Rescue and Purification
The recombinant Ad7 genomes were released from the plasmid backbone by digestion with
AsiSI. The digested plasmids were buffer-exchanged using a StrataPrep PCR purification kit
(Agilent Technologies, Santa Clara, CA, USA). All transfections were performed in 6-well plates
as described by Polyfect Transfection reagent (Qiagen, Valencia, CA, USA). The linearized Ad7-∆E1 and
Ad7-∆E3 gDNA was transfected into 293 cells, and scAd7 gDNA was transfected into 293-Ad7-Fiber
cells (Figure 1). GFP and DsRed expression were used to track foci as the viruses began to rescue.
Viruses were released from infected cells by 3 freeze–thaw cycles and amplified in sequential
passages in the complementing host cell lines. The viruses were amplified and purified as
previously described for wt Ad7. The virus particle quantity was determined on a NanoDrop
Lite spectrophotometer (Thermo Fisher) with an OD260. Ad7-∆E1, Ad7-∆E3, and scAd7 produced
4095, 10,600, and 14,400 vp/cell, respectively.
2.6. In Vitro Reporter Gene Expression and Luciferase Assay
The indicated cell lines were grown in 6-well tissue culture treated plates and infected with 50 vp/cell
(Corning, Corning, NY, USA). Images were taken at 24 and 72 h post-infection (Figure 2). The luciferase
activity of the viruses was measured by infecting (50 vp/cell) 293, 293-Ad7-Fiber, and A549 cells grown in
96-well black assay plates (Corning, Corning, NY, USA). At 24 h time points, the cells were lysed with
5× passive lysis buffer and luciferase activity was detected by adding 50 µL of luciferase activity reagent
(LAR) (Promega, Madison, WI, USA). The plate was shaken on an orbital shaker, and luciferase activity
was measured using a Beckman Coulter DTX 880 Multimode Detector (Figure 2).
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All pictures were imaged at the same light intensity for comparison of reporter gene expression.
The luciferase kinetics of each virus was lso examined by infecti g 293, 293-Ad7-Fiber, and A549 c lls
with the indicated virus s at 50 vp/cell. Luciferase expression was determined at 24 h intervals for six
days. The luciferase expression kinetics of th Ad7-∆E1, Ad7-∆E3, and scAd7 are shown in panels B, C,
and D, respectively. Dat are expressed as relative luminescence units (RLU) a d error bars indicate
sta ard e ror for 4 plate replicat s.
2.7. In Vitro qPCR of Viruses
Quantitative PCR (qPCR) was performed using a ViiA7 Sequence detection system
(Applied Biosystems, Warrington, UK). Table 1C shows the primers used for the detection of human
β- ctin (ACTB), hexon, fiber, GFPLuc, and DsRed genes. Both 293 and A549 cells were grown in 6-well
tissue culture plates and infected with the indicated virus at 50 vp/cell in 5% FBS DMEM. Total DNA
was isolated from the cells at 24 and 72 h post-infection using the DNAeasy Blood and Tissue Kit
(Qiag Valencia, CA, USA). Standard curves were made for each quantitated gene, and ACTB was
used s a standard to det rmine gen copies/cell. Real-time qPCR was do e using Power SYBR Green
PCR Master Mix, 100 ng of purified total DNA, 3.0 µM primers, and the following reacti conditions:
95 ◦C for 15 s, 56 ◦C for 15 s, and 72 C for 15 s (40 ycles).
2.8. Western Blot
To compare Ad7 hexon expres ion betwe n the devel , fl e t 293 ce ls were
infected with 500 vp/cell of the indicated virus. t ◦ 5 2 and
harvested at 48 h. Cells were denatured using Laemmli buffer plus 2 mercaptoethanol and boiled
at 100 ◦C for 10 min. The sample was then passed through a QIAshredder (Qiagen), loaded onto a
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12.5% SDS-PAGE gel, and separated using electrophoresis. Protein was transferred to a nitrocellulose
membrane and blocked for 30 min with 5% milk in TBST. Primary antibody was sera from a
Balb/c mouse infected with 1010 vp of wtAd7 virus through the intramuscular route and bleed
2 weeks later. The membrane was incubated in primary antibody at 1:200 and mouse anti-GAPDH
(sc-47724; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) at 1:2000 in TBST 1% milk overnight at 4 ◦C.
After 3 washes in TBST, the membrane was incubated with goat anti-mouse-HRP conjugated antibody
(Millipore Sigma, Burlington, MA, USA) at 1:2000 in TBST 1% milk for 1 h at room temperature
(RT). After incubation, the membrane was washed and developed with SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific, Waltham, MA, USA).
2.9. Virus Progeny Assay
To examine the virus progeny produced after infection of noncomplementing cells lines, A549 cells
were infected with each virus at an MOI of 1. MOI was determined by FACS on serial dilutions of each
virus to determine the FACS infectious units (IFU)/mL (Table S1). The A549 cells were infected for 1 h,
washed twice with PBS, fresh DMEM 10% FBS was added, and they were incubated at 37◦C with 5%
CO2. Cells were harvested at 48 h by spinning down the cells, discarding supernatant, and suspending
cells in 300 uL Ad-tris buffer. Next, three consecutive freeze–thaws were performed to release the
virus progeny, and all of this supernatant was plated on fresh A549 cells. Cells were harvested for
flow cytometry at 48 h and 7 days post-infection with the freeze/thawed supernatant. Cells were
washed, fixed in 1% formalin, and then analyzed for GFP expression on a Cytek DxP10 flow cytometer.
Infections were performed in triplicate.
2.10. Anti-Ad7 Neutralization Titer
Human desmoglein (hDSG) transgenic mice were immunized intramuscularly with
1010 vp per mouse of Ad7-∆E1, Ad7-∆E3, or scAd7Adenovirus vectored vaccination, which has
been shown to induce rapid and strong humoral and cellular immune responses [21,22]. Therefore,
two weeks post-immunization, the mice were sacrificed, and sera was tested for anti-Ad7 neutralizing
antibodies (NAbs). Sera was heat inactivated at 56 ◦C for 30 min before a serial 2-fold dilution was
performed in a 96-well black plate (3603 Corning). Naïve mouse serum was used as negative controls.
Fifty microliters of Ad7-dE3 expressing GFP-Luciferase (1 × 108 Ad-GL vp/mL) was then added to the
sera dilutions and incubated at 37 ◦C for 1 h. Next, 50 µl of A549 cells at 1 × 105 cells/mL was added to
each well, and the plates were incubated for 20 h at 37 ◦C and 5% CO2 before readout. The luciferase
activity was determined as described above. Neutralizing antibodies titers were determined as the
reciprocal dilution to inhibit 50% of luciferase activity as compared to no serum controls.
2.11. Elipsot
Ninety-six-well polyvinylidene difluoride-backed plates (MultiScreen-IP, Millipore, Billerica, MA)
were coated with 50 µL of anti-mouse IFN-γ mAb AN18 (5 mg/mL; Mabtech, Stockholm, Sweden)
overnight at 4 ◦C. The plates were blocked with cRPMI medium at 37 ◦C for 1 h. Splenocytes were
isolated from mice using a 70 µm Nylon cell strainer (BD Labware, Franklin Lakes, NJ, USA), red blood
cells were lysed using ACK lysis buffer, and the splenocytes were resuspended at a concentration
of 5 × 106 splenocytes/mL. Human DSG transgenic mice are on a mixed genetic background so
antigen-presenting cells were created. Naïve hDSG splenocytes were isolated and infected with
an Ad5-∆E1/3 replication-defective virus expressing GFP-Luciferase at 5000 vp/cell and incubated
overnight at 37 ◦C with 5% CO2. Single-cell suspensions of splenocytes from vaccinated mice
were incubated 1:1 with APCs in duplicate and incubated overnight at 37 ◦C with 5% CO2. The
plates were washed 6×with PBS and incubated with 100 µL of biotinylated anti-mouse IFN-γ mAb
(1:1000 dilution; Mabtech) diluted in PBS with 1.0% FBS for 1 h at RT. Plates were washed 6× with PBS
and incubated with 100 µL of streptavidin–alkaline phosphatase conjugate (1:1000 dilution; Mabtech,
Cincinnati, OH, USA) diluted in PBS 1.0% FBS. After 1 h at RT, the plates were washed 6×with PBS.
Viruses 2019, 11, 413 7 of 12
To develop, 100 µL of BCIP/NBT (Plus) alkaline phosphatase substrate (Thermo Fisher) was added
to each well, and development was stopped by washing several times in dH2O. The plates were
air-dried and spots were counted using an automated ELISpot plate reader (AID iSpot Reader Spectrum,
Oceanside, CA, USA). Results are expressed as spot-forming cells (SFC) per 106 splenocytes.
3. Results
3.1. Development of a Single-Cycle Ad7 Virus
We developed a single-cycle Ad7 virus (scAd7), along with replication-competent and
replication-defective Ad7 viruses, in order to examine the scAd7 virus’s potential as a vaccine candidate.
Reporter genes were inserted to evaluate these viruses using in vitro studies. The replication-competent
Ad7 virus (Ad7-∆E3) has an eGFP-Luciferase (GFP-Luc) fusion expression cassette running off a CMV
promoter in place of the nonessential Ad E3 gene (Figure 1A) and can produce infectious virus without
any additional genes. The replication-defective Ad7 virus (Ad7-∆E1) has the essential E1 gene deleted
and relies on E1 to be supplied by a complementing 293 cell line in order to replicate (Figure 1B).
Since E1 is required for replication, this virus will not replicate its genome or produce any virus
outside of the complementing 293 cell line. The single-cycle Ad7 (scAd7) has a deletion of both the
E3 gene and the fiber gene, which is an essential structural gene supplied in trans by a complementing
293-Ad7-Fiber cell line (Figure 1C). When scAd7 is grown outside of the 293 Ad7-fiber cell line, it only
produces fiberless virus, which has severely reduced infectivity [15,16]. Therefore, the scAd7 virus will
replicate its genome ≥10,000-fold and express Ad7 viral components but will only assemble fiberless
particles that have impaired infectivity (Figure 1C). We used DsRed as the reporter gene replacing the
Ad fiber gene, which runs off the Ad major late promoter (MLP) during replication. This scAd7 virus
will express Ad7 genes, GFP, luciferase, and DsRed transgenes in human cells.
3.2. In Vitro GFP Expression and Luciferase Activity
To examine reporter gene expression in complementing and noncomplementing cells lines, 293,
293-Ad7-Fiber, and A549 cells were infected with all three Ad7 viruses at 50 vp/cell. Images were taken
at 24 and 72 h post-infection. The scAd7 virus showed equivalent GFP expression in all three cell lines.
The replication-defective Ad7-∆E1 virus showed the best GFP expression in the E1 complementing
293 cells, whereas the replication-competent Ad7-∆E3 virus showed the greatest levels of expression in
A549 cells (Figure 2A). This was further supported by evaluating the luciferase activity of the three Ad7
viruses at different time points (Figure 2B–D). As with the florescence expression, the Ad7-∆E1 virus
showed the strongest luciferase activity in 293 cells, while the Ad7-∆E3 virus showed the strongest
activity in A549 cells. Peak luciferase activity was observed at 3 days post-infection for all viruses.
3.3. Ad7 Hexon Expression and gDNA Replication In Vitro
The deletion of the Ad7 fiber gene and insertion of the GFP-Luciferase and DsRed transgenes
were confirmed by PCR amplification of virus genomic DNA (Figure 3A). No Ad7 fiber gene was
detected in the viral genomic DNA (gDNA) of the scAd7 virus confirming successful deletion of this
gene and replacement with DsRed.
In contrast to the Ad7-∆E1 replication-deficient virus, the scAd7 virus can express Ad7 protein
products in noncomplementing cells and therefore potentially increase the anti-Ad7 immune response.
To confirm strong Ad7 protein expression in the scAd7 virus, a Western blot for Ad7 hexon was
performed (Figure 3B). Noncomplementing A549 cells were infected with the indicated virus at
500vp/cell, washed, incubated for 48 h, and cell lysates were collected. No Ad7 hexon expression was
detected in the Ad7-∆E1 infection because this virus is not able to replicate its genome or produce Ad7
proteins outside of E1 complementing cells. However, the scAd7 virus had strong hexon expression,
which was comparable to that of the replication-competent Ad7-∆E3 virus.
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To further evaluate the scAd7 virus’s ability to replicate its gDNA, we infected complementing
293 cells and noncomplementing A549 cells with the three viruses and determined the relative genome
copies at 24 and 72 h post-infection by real-time quantitative PCR (qPCR) (Table 1). As expected,
all three Ad7 viruses were able to replicate their gDNA in 293 cells (Figure 3C). However, in the A549
cells, the replication-defective Ad7-∆E1 was not able to replicate its gDNA, whereas the scAd7 virus
was able to replicate its gDNA in A549 cells which do not have a complementing fiber gene (Figure 3D).
The scAd7 virus had similar gDNA replication kinetics as compared to the replication-competent
Ad7-∆E3 virus in the A549 cells.
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Figure 3. In vitro Ad7 hexon expression and gDNA replication. The absence of the fiber gene and
the presence of the DsRed transgene in the scAd7 viral genomic DNA was confirmed by PCR (A).
Hexon protein expression in noncomplementing cells was confirmed by Western blot of A549 cells
infected with the indicated virus at 500 vp/cell and harvested after 48 h. GAPDH is used as a cellular
control (B). In addition, we quantitated the gDNA replication kinetics of all three Ad7 viruses in E1
complementing 293 cells (C) and noncomplementing A549 cells (D). This was achieved by quantifying
the introduced genes, DsRed and GFPLuc, and the structural genes, fiber and hexon. Gene copies
are displayed per cell as determined by the ACTB gene. Real-time qPCR was performed in triplicate,
and error bars indicate SEM.
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3.4. scAd7 Virus Infection Produces Virus Progeny with Impaired Infectivity
To confirm that infection by the scAd7 virus produces virus progeny with impaired infectivity,
noncomplementing A549 cells were infected at an MOI of 1 with the indicated virus for 1 h, washed,
and incubated for 48 h. This initial infection showed comparable numbers of GFP+ cells (Figure 4A,B).
These infected cells were harvested at 48 h, freeze/thawed to release the virus progeny, and then all
of the supernatant was used to infect new A549 cells. GFP+ cells were then quantified at 48 h and
7 days post-infection with the freeze/thawed supernatant (Figure 4A,B). The replication-competent
Ad7-∆E3 showed significant production of infectious virus particles in the noncomplementing cell line,
while the replication-deficient Ad7-∆E1 did not. The scAd7 virus showed severely reduced infectivity
of virus progeny (Figure 4A,B). There is limited transduction of the fiberless virus due to interactions
between the penton base and cellular αvβ integrins; however, there is no amplification and spread of
the fiberless virus outside of the fiber-complementing cell line (Figure 4B).
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Figure 4. Virus progeny of the three Ad7 viruses after infection of noncomplementing A549 cell lines.
Noncomplementing A549 cells were infected at an MOI of 1 with the indicated virus. At 48 h after
this initial infection, flow cytometry was performed to examine GFP+ cells (A) and quantitate the
percent GFP+ cells (B). A duplicate well of infected cells was harvested, freeze/thawed three times
to release virus progeny, and the supernatant was added to new A549 cells. After addition of the
freeze/thaw supernatant, cells were harvested for flow cytometry 48 h and 7 days after infection to
examine the presence of infectious virus progeny. Infection was performed in triplicate, and error bars
represent SEM.
3.5. In Vivo Immunogenicity of the Ad7 Vaccine Constructs
Human desmoglein 2 (hDSG) was determined to be the cellular receptor for Ad7 [23].
Human DSG transgenic mice were immunized via the i.m. route with 1010 vp/mouse of the indicated
virus and sacrificed 2 weeks later. An anti-Ad7 neutralization assay was performed to evaluate
neutralizing antibodies (Figure 5A). All three Ad7 viruses showed significant anti-Ad7 antibodies.
However, Adenovirus does not replicate in mice [24], so differences between the three viruses were not
observed. In addition, we observed a cellular immune response against the reporter gene luciferase in
all three viruses (Figure 5B).
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4. Discussion
Adenovirus type 7 infection is associated with acute respiratory disease. However, the vaccine to
protect against Ad7 infections is only licensed for use in the military and uses wild type virus which
can be shed in the stool for up to 28 days after immunization. Here we developed a single-cycle Ad7
virus as a safer Ad7 vaccine for use in the general public. The single-cycle virus is deleted for the
fiber protein and therefore assembles fiberl ss Ad progeny during infection of noncomplementing
cells. Interactio between fiber and the cellular protein hDSG is t e primar mode of transduction for
Ad7 [23]; therefore, this fiberless virion has severely reduced infectivity.
Since we do not have a cell line that complements the Ad7 E1 genes, we used 293 cells that express
complementing Ad5 E1 genes. We were able to produce our Ad7-∆E1 virus; however, the resulting
virus had a high virus particle to IFU ratio (Table S1). This is not unusual since E1 genes from different
species of Adenovirus do not always fully complement each other and have to be grown in E1 and
E4 complementing cell lines [25]. Establishing a cell line that expresses the species B E1 genes may
significantly improve the viral particle to IFU ratio.
This scAd7 virus shows s rong Ad7 hex n expression (Figure 3B) and stro g gDNA replication
(Figure 3D), even in noncomplementing A549 cell lin s. These l vels are comp rable to that of
the Ad7-∆E3 replication-competent virus. By contrast, the Ad7-dE1 virus showed undetectable
hexon expression after infection of noncomplementing A549 cells. While we did not detect any late
gene synthesis after infection with our E1 deleted virus, studies using a high MOI infection (>500)
of A549 cells detected low late gene expression; however, it was not indicative of efficient virus
replication [26].
Our in vitro studies support that the virus progeny produced from a scAd7 infection of
noncomplementing cells has severely reduced infectivity (Figure 4). The limited transduction seen
with the scAd7 virus in the virus progeny assay could be attributed to minor interacts between the
penton base and cellular αvβ integrins [15]. In vivo studies showed development of strong anti-Ad7
neutralizing antibodies by all Ad7 viruses (Figure 5A). However, differences between the Ad7 virus
constructs could not be observed due to the lack of permissive Adenovirus replication in mice [24].
In addition, there is variation in hDSG receptor expression in different tissues of the transgenic mice [17].
While intranasal or enteric route of immunization might increase transgene expression in these mice,
replication of Adenovirus would still not occur. A small animal model that was transgenic for hDSG
and permissive for human Adenovirus replication would greatly improve our ability to evaluate the
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scAd7 vaccine platform. Unfortunately, there is currently no available small animal model to optimally
support preclinical studies.
The scAd7 virus currently has reporter transgenes; however, future work could examine
substituting these genes for pathogen genes, such as the influenza virus hemagglutinin, in order to
create a multivalent vaccine vector. In fact, a single-cycle construct based on Ad6 has already shown
promise at inducing anti-influenza and anti-Ebola virus immunity [27,28]. By replacing the GFP,
luciferase, and DsRed genes, it could be possible to create a single-cycle Ad7 virus that has utility against
itself, and three other genes that could easily represent three distinct pathogen genes. In addition,
this single-cycle approach could be applied to other medically important Ad types, such as Ad4, which
is also associated with ARD.
Our scAd7 virus combines the safety advantages of a replication-defective virus with the increased
Ad7 protein expression of a replication-competent virus. Virus progeny produced outside of the
complementing cell line have impaired infectivity. However, the scAd7 virus is potentially more
immunogenic than a replication-defective virus because it retains the ability to replicate its gDNA,
thus increasing Ad7 protein expression. Due to these advantages, we believe that scAd7 viruses should
be further studied as an alternative, safer Adenovirus 7 vaccine.
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